The Significance of CD13/Aminopeptidase N in Interstitial Lung Diseases(びまん性肺疾患に対する分子生物学的アプロ-チ : 間質性肺炎から肺気腫まで)(第24回日本気管支学会総会)

  • Tani Kenji
    Third Department of Internal Medicine, School of Medicine, Tokushima University
  • Endo Takeshi
    Third Department of Internal Medicine, School of Medicine, Tokushima University
  • Sone Saburo
    Third Department of Internal Medicine, School of Medicine, Tokushima University

この論文をさがす

説明

CD13/aminopeptidase N (E.C.3.4.11.2) is an ectoenzyme located in the outer cell membrane in a variety of cells. Since CD13/aminopeptidase N was shown to induce in vitro chemotactic migration of human lymphocytes, we examined here the significance of CD13/aminopeptidase N in pulmonary sarcoidosis and radiation pneumonitis caused by a single-dose thoracic irradiation (15 Gy) in a rat model. The activity of aminopeptidase in bronchoalveolar lavage fluid (BALF) was significantly higher in sarcoidosis patients than in normal volunteers (NV) and control patients (CP). CD13/aminopeptidase N protein was detectable in alveolar macrophages (AN) from sarcoidosis patients at higher levels than in those from NV. Higher chemotactic activity for lymphocytes was detected in the BALF from sarcoidosis patients that in that from NV, and the activity was significantly decreased by the treatment with bestatin, an specific inhibitor for aminopeptidase N. Significantly increased CD13/aminopeptidase N activity and expression were also detected in BALF and AM obtained from irradiated rats at 4 weeks after irradiation compared with the activity in unirradiated rats. Chemotactic activity for normak rat lymphocytes was detected in BALF from irradiated rats at 4 weeks, and approximately 60% of the activity was inhibited by pretreatment of BALF with bestatin. This study suggests that CD13/aminopeptidase N may play an important role as a lymphocyte chemoattractant in lymphocyte-mediated alveolitis in interstitial lung diseases.

収録刊行物

  • 気管支学

    気管支学 23 (8), 731-734, 2001

    特定非営利活動法人 日本呼吸器内視鏡学会

参考文献 (7)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ